Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial
Eli Lilly and Company
Kausik K Ray; Ena Oru; Robert S Rosenson; Jeremiah Jones; Xiaosu Ma; Jennie Walgren; Axel Haupt; Subodh Verma; Daniel Gaudet; Stephen J Nicholls; Giacomo Ruotolo